CardioWise™ Acquires Worldwide Rights to New Cardiac CT Analysis, Patents, Software and Technology Through License Agreement with Johns Hopkins Technology Ventures

Share Article

SQuEEZ heart function analysis software provides extraordinary, mobile-friendly, and easy-to-read color models to help physicians diagnose heart disease.

CardioWise, Inc. Logo
CardioWise can then make the SQuEEZ analysis available to caregivers and patients on any mobile device in an easy-to-read, quantitative color model, allowing patients to participate in decisions about their care.

CardioWise, Inc., is pleased to announce that the company has acquired the worldwide rights to SQuEEZ heart function analysis software, and an associated pending patent from Johns Hopkins Technology Ventures through a license agreement. The U.S. Patent application was filed April 10, 2014 and uses high resolution cardiac CT to analyze cardiac wall motion that provides extraordinary new insights to help physicians diagnose heart disease.

The research and development of SQuEEZ was completed by co-inventors Elliot R. McVeigh, Ph.D. and Amir Pourmorteza, Ph.D., both of the Johns Hopkins University School of Medicine at the time the invention was made.

Over 10 million patients per year in the U.S. receive cardiac CT studies, but physicians can only subjectively evaluate heart wall motion, one of the most important keys to diagnosis. The SQuEEZ patent is based on the ability to track the endocardium (heart wall) as it moves during the contraction of the heart to allow quantitative assessment of regional heart wall motion. A key aspect of the invention is its ability to use anatomical markers to follow heart wall motion as the heart moves through a complete cycle. Individual patient data are compared regionally within the left ventricle of the heart to a normal patient database that was compiled by the inventors. Using the CardioWise machine learning, cloud-based Software as a Service database information, patient-specific SQuEEZ values in each region of the left ventricle can be related to the normal data range, with the potential to improve diagnosis and determine outcomes in follow-up. It takes only a single heartbeat to acquire the data set required for the analysis, dramatically reducing radiation dose.

Jack Coats, CEO of CardioWise, Inc., said, “We are very pleased that Johns Hopkins Technology Ventures has licensed this capability to CardioWise. The pioneering efforts of the inventors over the past few years to develop the method that has resulted in SQuEEZ have brought extremely important new quantitative information to evaluate and treat patients with cardiovascular disease. CardioWise can then make the SQuEEZ analysis available to caregivers and patients on any mobile device in an easy-to-read, quantitative color model, allowing patients to participate in decisions about their care. This technology will also have the capability to use machine learning and artificial intelligence to help predict outcomes and direct patient care, saving lives and reducing the cost of healthcare.”

CardioWise™ is commercializing patented, Cardiac Computed Tomography (CT) machine learning analysis software that produces a quantified image model of the human heart. CardioWise heart analysis software combined with cardiac CT is a single diagnostic test that can provide quantitative analysis of heart wall motion, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jack Coats, CEO
@VIC_tvd
since: 09/2013
Follow >
CardioWise Inc.
since: 01/2015
Like >
VIC Technology Venture Development

Visit website